2025-09-14T21:07:27-04:00 2024-12-31 990EZ 2024-01-01 854372947 Kras Cancer Connect Inc % Teresa D Conneran KRAS 7042990814 12519 PORTMARNOCK CT Charlotte NC 282776623 Teresa Conneran Founder Director 2025-09-15 false 2024 2025-03-06 01:10:19Z X X https: www.kraskickers.org X X 175857 X 175632 225 0 0 0 175857 135513 18213 142299 296025 -120168 382422 0 262254 X 382422 274231 382422 274231 0 11977 382422 262254 To empower people affected by KRAS and other RAS cancers through education advocacy and resources that connect patients with research and community helping them advocate for their best survivorship and ensuring no one faces cancer alone. IIn 2024 KRAS Cancer Connect d b a KRAS Kickers invested deeply in professional conference engagement and advocacy to ensure that patients with KRAS and other RAS cancers were represented at the highest levels of oncology. As members and participants in leading professional societies including ASCO AACR SITC and IASLC we were recognized as a consistent trusted voice for the KRAS community. Within these arenas the KRAS Kickers name has become synonymous with patient empowerment: when research leaders clinicians or industry stakeholders discuss KRAS they know our community is present.Our Director and volunteers attended these conferences not to recruit patients but to educate build awareness and break down barriers between science and survivorship. We participated in poster sessions roundtables and networking events always bringing the voice of patients directly into the research ecosystem. These engagements ensured that trial designers pharmaceutical partners and oncologists heard first-hand the needs and priorities of patients navigating KRAS and other RAS mutations. At the same time we distilled new insights into plain-language educational updates and shared them widely through Facebook groups newsletters YouTube sessions and open community forums.We also developed and distributed thousands of reviewed educational materialsbooklets postcards stickers and conference handoutsthat carried accurate accessible information about KRAS and RAS cancers. These were conversation starters and learning tools designed to empower patients and their families in clinic visits and community discussions. Our advocacy extended through cross-nonprofit collaborations where we joined forces with partner organizations to amplify shared goals in biomarker awareness equitable access to research and survivorship support. Together we raised visibility for RAS cancers across multiple disease communities and elevated the patient perspective in conversations that shape the future of oncology.This program area represented approximately $145,000 in 2024 program spending and its impact was visible in both directions: the oncology community increasingly views KRAS Kickers as the trusted patient bridge in RAS discussions and patients everywhere benefit from timely accessible information and resources that help them advocate for their best survivorship. 0 145000 KRAS Cancer Connect d b a KRAS Kickers hosted open-access webinars where leading clinicians and researchers spoke directly with patients. These sessions gave participants the rare opportunity to hear from experts at the cutting edge of oncology and to ask questions in real time. Our role was to ensure those answers did not remain locked in scientific jargon but were translated into clear practical insights that patients and families could apply to their own care.We emphasized not just what to ask but what to listen forhow to recognize key details map choices within a decision-tree of options and apply that understanding in conversations with ones own doctor. Researchers frequently remarked on the depth of understanding and curiosity shown by our community; patients were not passive recipients of information but engaged partners shaping informed decisions for life while living with cancer.Beyond virtual sessions we organized onsite lab visits at Johns Hopkins and Moffitt Cancer Center where patients observed science in action met investigators and asked candid questions about research. We also convened a KRAS Kickers community event in Charlotte NC building connection and confidence as people navigated rapidly evolving options. These experiences demystified the research process reduced barriers to understanding clinical trials and helped patients see themselves as active participants in the research ecosystem rather than passive recipients of care. Our separate peer support group remains private and unrecorded to protect confidentiality.Approximately $79,000 supported expert speakers platforms and tools moderator support travel and content development in 2024. These efforts advanced survivorship through education and empowerment closing gaps in understanding and accesswhat our community calls KRAS holesso no one faces cancer alone. 0 79000 KRAS Cancer Connect d b a KRAS Kickers believes patients lived experience is as valuable as scientific expertise. In 2024 we provided stipends to patients participating in scientific and medical meetings recognizing both the financial burden of treatment appointments and the value of their time and insights. These stipends ensured patients could engage fully in education and advocacy without additional hardshipand more importantly affirmed that their contributions matter.We also supported moderators and peer leaders with stipends for sustaining our community: sharing updates from conferences and webinars translating research into plain language guiding discussions and ensuring accuracy across channels. This created a vital looppatients attend and learn; moderators communicate and amplify; the wider community receives timely trustworthy information.No clinicians or researchers were paid or provided honoraria. We flipped the script by investing directly in patients and peer leadership centering the people most affected by KRAS and other RAS cancers. Approximately $15,000 supported stipends and modest speaker expenses where applicable in 2024 strengthening patient leadership consistent knowledge flow and a culture that eliminates gaps and KRAS holes in care. 0 15500 239500 X Sandra Shaw Director 15 0 0 0 Christine Thomas Director 2 0 0 0 Emily Young Director 2 0 0 0 Patricia Gemmil Director 6 0 0 0 Teresa Conneran Founder Director 60 42549 0 0 false false false false false false false false false DE NC Teresa D Conneran 12519 Portmarnock Court Charlotte NC 28277 6026143176 false false false false false false false false false false false NONE NONE true X 0 0 0 0 175632 175632 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 175632 175632 148948 26684 0 0 0 0 225 225 0 0 0 0 0 0 0 0 0 0 0 0 175857 0 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED Part I, line 16 | Other Expenses:, Amount:| Exhibition & Presentations, $117693.00| Educational Stipends, $4736.00| Other Expenses, $19870.00| Part II, line 26 | Liabilities Name:, BOY Amount:, EOY Amount:| Accounts Payable, 0, $11977| Part IV, List of Officers | Employee Name:, Description:| Teresa Conneran, Compensation was paid to the Director via a 1099 issued to her S corporation no additional benefits were provided. The Director routinely works 60+ hours per week in service of the organization.| List of Officers (Part IV),line 50 | Explanation:| Compensation: The Directors compensation for 2024 was reported in Part IV. Compensation was issued via 1099. No additional benefits were provided. Program Service Accomplishments (Part III),line 3 | Explanation:| Stipends reported were provided only to patients and moderators to offset participation costs and to honor their contributions of time and expertise. No clinicians or researchers were paid or provided honoraria. The organization does not conduct or fund scientific research. All activities described are educational advocacy or patient support programs. Revenue (Part I),line 1 | Explanation:| The organization did not maintain restricted funds in 2024; all contributions were unrestricted. Revenue (Part I),line 6 | Explanation:| KRAS Cancer Connect did not conduct any campaign fundraisers in 2024. Net Assets and Fund balances (Part II),line 21 | Explanation:| Prior to 2024 all KRAS Kickers related program activity was reported under the Dusty Joy Foundation. KRAS Cancer Connect received its IRS determination letter in September 2023. Effective January 2024 the net assets of approximately $382,000 represented funds transferred . 2024 is the first year of independent reporting for KRAS Cancer Connect d b a KRAS Kickers.